However, the therapeutic efficacy of monotherapy CDK4/6i in PC has shown to be largely undermined by compensatory cell cycle regulatory pathways, including the upregulation of Cyclin E1 [36] and the loss of RB [37]. The gene discussed is CDK4; the disease is pachyonychia congenita.